HOME
LOGIN/REGISTER
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Most Read Articles
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1519
The results of the recently published FOURIER trial have shown a reduction in cardiovascular events with addition of the PCSK9 inhibitor evolocumab (Repatha) to statin therapy in patients with atherosclerotic cardiovascular disease (ASCVD).  read more...
More from issue 1519
Coming Soon
Drugs for Allergic Disorders
Oxymetazoline Cream (Rhofade) for Rosacea
Valbenazine (Ingrezza) for Tardive Dyskinesia
Ocrelizumab (Ocrevus) for Multiple Sclerosis
Prescription Drug Prices in the US
Previous Issues
© 2017 The Medical Letter, Inc.